FABP4 and neoplasm: However, even if FABP4 is detected both in OvCA cells and CAAs, systemic treatments targeting tumor and host FABP4 are not more effective in decreasing metastatic nodules than host FABP4 knock-down [19, 20], highlighting the prominent role of FABP4 in TME [18–20].